Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office VANCOUVER, British Columbia, June 10, 2026 (GLOBE NEWSWIRE) — via IBN – Optimi Health Corp. […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.